The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2020 | New insights in the biology of myeloproliferative neoplasms
Anna Rita Migliaccio, PhD, University of Bologna, Bologna, Italy, discusses novel insights into the pathogenesis of myelofibrosis and the changes involved in the development of myeloproliferative neoplasms from benign forms of disease. Dr Migliaccio outlines the use of ruxolitinib, which improves symptoms of myelofibrosis but highlights the need for curative therapies, including treatments targeting TGF-beta and p-selectin which have shown in mouse models to have curative effects. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
